News

Dermatology Times spoke with Leah Howard, JD, of the NPF, and Trisha, the mother of a young girl with psoriasis, to discuss Otezla's implications in the therapeutic landscape.

The oral TYK2 inhibitor demonstrated biologic-level efficacy.

Keep up with the latest headlines in dermatology from the past week, including research into "zombie cells" in skin disorders, tartrazine's effects on skin transparency, and more.

In case you missed it, this week we had news about phase 2 initiation of EVO756 for chronic inducible urticaria, IBI363's Fast Track Designation for advanced melanoma, Arcutis' enrollment of the last patient in ARQ-255 trial for alopecia areata, and more.

A recent study investigated the acceptability, barriers, and facilitators associated with digital health tools.

The JAK1 inhibitor provided significant relief for 2 patients with refractory PN.

Researchers conducted a web-based survey to gain insights into current clinical practice for PN in Japan.

The study is actively recruiting participants at multiple sites across the US.

New research shows the 675-nm laser enhances skin texture and rejuvenation, making it a valuable tool for various dermatological conditions.

Citius' recently-approved Lymphir has been added to the National Comprehensive Cancer Network's Clinical Practice Guidelines in Oncology.

The data was presented at the European Society of Contact Dermatitis in Dresden, Germany, this week.

Arcutis' study of ARQ-255 aims to address the lack of FDA-approved topical treatments for alopecia areata, a condition affecting roughly 1 in 500 people.

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry.

The study stated that enhancing patient education and psychological support can improve rosacea management and quality of life.

The study, published in Dermato, showed that 92% of NMSC tumors showed measurable changes in depth of invasion from one image to the next.

Although clinicians showed similar antibiotic prescribing rates, the study highlights a need for better adherence to HS treatment guidelines across all specialties.

The PD-1/IL-2α bispecific antibody fusion protein is intended for patients with unresectable locally advanced or metastatic melanoma.

The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.

The review found that patients with PN are approximately 1.3 times more susceptible to depression and 1.9 times more likely to experience anxiety.

This week’s collection of the latest dermatologic studies includes the implementation of an action plan for patients with atopic dermatitis, early childhood eczema and the risk of allergic multicomorbidities, and more.

The study showed significant improvement in repigmentation with silymarin, with patients of different sexes benefiting equally, though monthly differences were not significant.

The phase 2 trial for EVO756, targeting mast cell-related CIndU, is now underway at 15 US study sites.

The 83-year-old patient was being treated for mycosis fungoides.

A recent study revealed a spectrum of photosensitivity in AD, with varying symptoms and sensitivities.

42 studies with 1027 cases evaluated drugs like bimatoprost and apremilast for vitiligo.

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Keep up with the latest headlines in dermatology from the past week, including new research into AI versus clinician detection of skin cancer, parasitic worms in wound healing, and more.

In case you missed it, this week we had news about the AHEAD atopic dermatitis treatment recommendations, positive long-term results for roflumilast cream 0.05% in pediatric patients, line-field optical coherence tomography for dermal fillers, and more.

Throughout the month of August, Dermatology Times covered psoriasis news related to Alumis Inc’s phase 3 trial of ESK-001 for plaque psoriasis, AbbVie’s Science of Skin event, and more.